CYTO
Watchlists:
Last updated: Saturday 15th February 2025
0.00
No Change
Prev Close:N/A
Open:N/A
Bid:N/A
Ask:N/A
52 Week Range
0.000.00
Volume:0
Mkt Cap:0 M
Financials
Financial Statements
CYTO - Income Statement (Annual)
| Dec-23 | Dec-22 | Invalid date | |
|---|---|---|---|
| Acquired In Process Rn D Income | 441277.0 | ||
| Basic EPS From Continuing Operations | -7.88 | ||
| Basic EPS Total | -7.88 | -29.13 | |
| Basic Weighted Shares Outstanding | 491258.0 | 910723.0 | |
| Basic Discontinuous Operations | -29.13 | ||
| Commission Expenses | 1137.0 | ||
| Cost Of Sales | 1 M | ||
| Depreciation | 119304.0 | ||
| Depreciation Unreconciled | 119304.0 | ||
| Depreciation And Amortization | 119304.0 | ||
| Diluted EPS Total | -7.88 | -29.13 | |
| Diluted Normalized Net Income/share | -7.88 | ||
| Diluted Weighted Shares Outstanding | 491258.0 | 893479.0 | |
| Diluted Discontinuous Operations | -2808.0 | ||
| Earnings From Equity Interest | -39557.0 | 709449.0 | |
| Earnings From Equity Interest Net Of Tax | -39557.0 | 709449.0 | |
| Gain On Sale Of Business | 305616.0 | ||
| Gain On Sale Of PPE | 61046.0 | ||
| Gain On Sale Of Security | 228302.0 | ||
| General And Administrative Expense | 3 M | 4 M | |
| Gross Operating Profit | 27287.0 | -1 M | |
| Impairment Of Capital Assets | -12 M | ||
| Income Before Tax | -7 M | -26 M | |
| Income Taxes | -10329.0 | ||
| Interest Income | 354093.0 | 1 M | |
| Interest Expense Non Operating | 2 M | 911869.0 | |
| Misc Other Special Charges | 346035.0 | ||
| Net Income From Total Operations | -4 M | -26 M | |
| Net Income Common Stockholders | -4 M | -26 M | |
| Net Income Continuous Operations | -7 M | -26 M | |
| Net Income Discontinuous Operations | 3 M | ||
| Net Non Operating Interest Income Expense | -1 M | -911869.0 | |
| Normalized Income | -5 M | ||
| Operating Income | -6 M | -27 M | |
| Operating Income Before Depreciation (EBITDA) | -5 M | -25 M | |
| Operating Expense | 6 M | 26 M | |
| Other Income Net | -188745.0 | -2 M | |
| Other Gand A | 3 M | 4 M | |
| Other Operating Expenses | -5 M | ||
| Other Taxes | 12738.0 | ||
| Rent And Landing Fees | 4 M | ||
| Research & Development Expense | 3 M | 20 M | |
| Research Expense | 3 M | 20 M | |
| Salaries And Wages | -4 M | ||
| Selling Gen & Administrative Expense | 3 M | 6 M | |
| Selling And Marketing Expense | 43055.0 | 2 M | |
| Selling Expense | 2 M | ||
| Special Income/charges | 12 M | ||
| Total Income Available For Interest Expense (EBIT) | -6 M | -25 M | |
| Total Common Shares Outstanding | 1 M | ||
| Total Net Income | -4 M | -26 M | |
| Total Ordinary Shares | 3 M | 3 M | |
| Total Revenues | 27287.0 | 305616.0 | |
| Total Expenses | 6 M | 27 M | |
| Total Revenue | 27287.0 | 305616.0 |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.